Saturday 17 October 2026
Export ANVS’s income statement to Excel — free account
Annovis Bio, Inc.
ANVS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 25.0% and free cash flow fell 329.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.99
0.06
−5.71%
Follow ANVS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(246.14%) | (220.61%) | (301.13%) | (703.68%) | |
| (157.74%) | (164.85%) | (190.43%) | (227.74%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(184.94%) | (165.39%) | (1,185.13%) | (315.88%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.27) | (1.25) | (0.95) | (1.16) | |
Free Cash Flow |
(24.98) | (25.62) | (26.53) | (43.34) | |
| Other line items | |||||
Cash ROIC |
(87.82%) | (70.42%) | (152.97%) | (299.43%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.00 | 0.89 | 0.65 | 0.88 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.27) | (1.25) | (0.95) | (1.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates